
LSZ102
CAS No. 2135600-76-7
LSZ102( LSZ 102 | LSZ-102 )
Catalog No. M13402 CAS No. 2135600-76-7
LSZ102 is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) with ERα transcription IC50 of 6 nM and ERα degradation IC50 of 0.2 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 132 | In Stock |
![]() ![]() |
5MG | 222 | In Stock |
![]() ![]() |
10MG | 372 | In Stock |
![]() ![]() |
25MG | 623 | In Stock |
![]() ![]() |
50MG | 887 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameLSZ102
-
NoteResearch use only, not for human use.
-
Brief DescriptionLSZ102 is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) with ERα transcription IC50 of 6 nM and ERα degradation IC50 of 0.2 nM.
-
DescriptionLSZ102 is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) with ERα transcription IC50 of 6 nM and ERα degradation IC50 of 0.2 nM; robustly causes inhibition of cell proliferation in MCF-7 cells with IC50 of 1.7 nM, inhibits the mRNA level of canonical endogenous ER target gene GREB1 with IC50 of 8.9 nM; demonstrates anti-tumor efficacy in the ER+ human breast cancer MCF-7 xenograft model (10 mg/kg).Breast Cancer Phase 1 Clinical.
-
In VitroLSZ-102 is a potent, orally bioavailable selective estrogen receptor degrader with an IC50 of 0.2 nM and currently in Phase I/Ib trials for the treatment of ERα positive breast cancer. LSZ-102 induces significant degradation of ERα after 24 h, when given as a 10 μM solution to MCF-7 cells. Robust inhibition of cell proliferation in MCF-7 cells is observed upon incubation with LSZ-102 with a half inhibitory concentration of 1.7 nM. Results demonstrate that LSZ-102 effectively inhibits the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 with IC50 of 0.3 nM.
-
In VivoTreatment of the mice with LSZ-102 once daily at 20 mg/kg results in significant tumor growth inhibition as compare to the control group treated with vehicle alone, resulting in tumor stasis (mean change in tumor volume of LSZ-102 vs control=%ΔT/ΔC of 2.4% on day 48, p<0.05). Dosing of 3 mg/kg solution of LSZ-102 in male Sprague-Dawley rats results in 33% bioavailability and a dose-normalized exposure of 620 nM?h.
-
SynonymsLSZ 102 | LSZ-102
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorEstrogen Receptor/ERR
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number2135600-76-7
-
Formula Weight470.462
-
Molecular FormulaC25H17F3O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO : 100 mg/mL 212.56 mM; H2O : < 0.1 mg/mL
-
SMILESO=C(O)/C=C/C1=CC=C(OC2=C(C3=CC=C(F)C=C3C(F)(F)C)SC4=CC(O)=CC=C42)C=C1
-
Chemical Name(E)-3-(4-((2-(2-(1,1-Difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tria GS, et al. J Med Chem. 2018 Apr 12;61(7):2837-2864.
molnova catalog



related products
-
SAR439859
SAR439859 is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD).
-
4-Hydroxytamoxifen
A selective estrogen receptor modulator (SERM) and the major active metabolite of tamoxifen.
-
Norethindrone
Norethindrone is a synthetic progestin, which mimic the actions of the endogenous ovarian hormone progesterone.